AbbVie, Genmab’s Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3

AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large B cell lymphoma—potentially setting up a battle with Roche’s Polivy.